vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and BingEx Ltd (FLX). Click either name above to swap in a different company.
BingEx Ltd is the larger business by last-quarter revenue ($143.2M vs $70.9M, roughly 2.0× Adaptive Biotechnologies Corp). Adaptive Biotechnologies Corp runs the higher net margin — 4.7% vs 2.2%, a 2.5% gap on every dollar of revenue.
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
ADPT vs FLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $70.9M | $143.2M |
| Net Profit | $3.4M | $3.2M |
| Gross Margin | 73.6% | 10.8% |
| Operating Margin | -27.1% | — |
| Net Margin | 4.7% | 2.2% |
| Revenue YoY | 35.1% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $70.9M | $143.2M | ||
| Q4 25 | $71.7M | — | ||
| Q3 25 | $94.0M | $141.2M | ||
| Q2 25 | $58.9M | $143.0M | ||
| Q1 25 | $52.4M | $141.0M | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $46.4M | $164.6M | ||
| Q2 24 | $43.2M | — |
| Q1 26 | $3.4M | $3.2M | ||
| Q4 25 | $-13.6M | — | ||
| Q3 25 | $9.5M | $6.1M | ||
| Q2 25 | $-25.6M | $7.5M | ||
| Q1 25 | $-29.9M | $27.6M | ||
| Q4 24 | $-33.7M | — | ||
| Q3 24 | $-32.1M | $3.4M | ||
| Q2 24 | $-46.2M | — |
| Q1 26 | 73.6% | 10.8% | ||
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | 11.1% | ||
| Q2 25 | 69.4% | 12.0% | ||
| Q1 25 | 67.6% | 10.0% | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | 11.3% | ||
| Q2 24 | 55.3% | — |
| Q1 26 | -27.1% | — | ||
| Q4 25 | -17.8% | — | ||
| Q3 25 | 10.9% | 1.4% | ||
| Q2 25 | -42.5% | 1.9% | ||
| Q1 25 | -56.4% | — | ||
| Q4 24 | -71.3% | — | ||
| Q3 24 | -70.3% | 4.0% | ||
| Q2 24 | -109.6% | — |
| Q1 26 | 4.7% | 2.2% | ||
| Q4 25 | -18.9% | — | ||
| Q3 25 | 10.2% | 4.4% | ||
| Q2 25 | -43.5% | 5.2% | ||
| Q1 25 | -56.9% | 19.6% | ||
| Q4 24 | -71.0% | — | ||
| Q3 24 | -69.1% | 2.1% | ||
| Q2 24 | -107.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $-0.17 | — | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.22 | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.31 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.6M | $561.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $505.9M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $77.6M | $561.1M | ||
| Q4 25 | $70.5M | — | ||
| Q3 25 | $55.0M | $628.6M | ||
| Q2 25 | $43.2M | $499.4M | ||
| Q1 25 | $50.6M | $592.4M | ||
| Q4 24 | $47.9M | — | ||
| Q3 24 | $38.1M | $517.4M | ||
| Q2 24 | $59.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | $218.8M | — | ||
| Q3 25 | $204.4M | — | ||
| Q2 25 | $179.7M | — | ||
| Q1 25 | $190.4M | — | ||
| Q4 24 | $202.7M | — | ||
| Q3 24 | $223.8M | — | ||
| Q2 24 | $241.6M | — |
| Q1 26 | $505.9M | $1.3B | ||
| Q4 25 | $512.7M | — | ||
| Q3 25 | $490.6M | $1.3B | ||
| Q2 25 | $496.6M | $1.2B | ||
| Q1 25 | $510.9M | $1.2B | ||
| Q4 24 | $539.4M | — | ||
| Q3 24 | $558.5M | $926.8M | ||
| Q2 24 | $584.9M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
